An2 Therapeutics, Inc.
Ticker: ANTX
| Insider | Title |
|---|---|
| Braden Michael Leonard | 10% or greater ownership |
| Capital Gp, L.p. Adjuvant | 10% or greater ownership |
| Capital Healthcare Fund Lp Ra | 10% or greater ownership |
| Capital Management, L.p. Ra | 10% or greater ownership |
| Capital Management, Llc Adjuvant | 10% or greater ownership |
| Capital Nexus Fund Ii, L.p. Ra | 10% or greater ownership |
| Eric Easom | Chief Executive Officer, Director |
| Gilbert Lynn Marks | Director |
| Global Health Technology Fund De, L.p. Adjuvant | 10% or greater ownership |
| Global Health Technology Fund, L.p. Adjuvant | 10% or greater ownership |
| Joseph S Zakrzewski | Director |
| Joshua M Eizen | See Remarks |
| Kabeer Aziz | Director |
| Kevin Michael Krause | Chief Strategy Officer |
| Lucy Day | Chief Financial Officer |
| Margaret M Fitzpatrick | Director |
| Melvin K Spigelman | Director |
| Michael Adrian Nazak | Chief Accounting Officer |
| Patricia A. Martin | Director |
| Paul Eckburg | Chief Medical Officer |
| Peter Kolchinsky | 10% or greater ownership |
| Rajeev M. Shah | 10% or greater ownership |
| Robin Shane Readnour | Director |
| Sanjay Chanda | Chief Development Officer |
| Stephanie Wong | Director |
| Stephen David Prior | Chief Strategy Officer |